SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community chatter focused on a potential breakout and significant price movement. Bullish sentiment is fueled by expectations of strong earnings and guidance, and some are pointing to potential tailwinds like future rate cuts and crypto integration. The stock's ability to break through the $30 resistance level is a key point of discussion.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid mixed sentiment, with some traders citing a potential bottom after a period of decline, while others express concerns about manipulation and the company's long-term prospects. A recent NFL apparel partnership is a key catalyst mentioned, though some question its impact, and overall discussion centers on whether the stock is poised for a rebound or further downside. Community members are actively debating analyst ratings and potential activist involvement.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as the company recently launched new AI chips aimed at competing with Nvidia and AMD in the data center market, generating significant buzz and a surge in stock price. Community discussions revolve around the potential impact of these chips, revenue projections, and whether Qualcomm can truly challenge the dominance of existing players. Some analysts express skepticism, citing the chips' specifications and disclosed customer base, while others highlight the company's shift towards AI infrastructure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors weigh the potential impact of a new web browser from OpenAI, a possible competitor to Google Chrome. Despite the concerns, many community members view the dip as a buying opportunity, emphasizing Google's diverse portfolio and strong position in AI and cloud computing.  Additionally, some analysts have recently raised their price targets for the stock, citing positive advertising and cloud channel checks.

Trump For President

Trump Crypto is trending amid mixed community sentiment, with some users discussing potential pumps and scams while others express political opinions related to Trump. Bullish investors are anticipating gains, while bearish investors are pointing to the coin's performance since launch. The coin seems to be moving in response to triggers related to its namesake figure.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a significant volume spike and discussions around its potential for a parabolic move. Community members are closely watching for continuation and a possible short squeeze, citing a very low float and insider ownership. Some traders are also pointing to a recent revenue growth update as a potential catalyst.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors react to the company's plans to cut up to 30,000 corporate jobs, with community members discussing the implications for the broader economy and the potential impact of AI and automation on the workforce. Some view the layoffs as a cost-cutting measure before earnings, while others speculate about a potential recession. Despite the concerns, some investors see the dip as a buying opportunity, drawing comparisons to past layoff announcements that preceded stock rallies.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a sharp decline following the pause of its Phase 3 trials for nex-z after a patient experienced liver problems, leading to a significant stock drop. The community is debating whether this is an overreaction and a buying opportunity, or a justified re-pricing due to potential issues with its leading program. Technical analysis suggests a potential rebound around the $15 support level, while some analysts remain optimistic about risk-mitigation strategies.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the company reclaims its original ticker symbol after Overstock's rebranding, sparking discussions of meme stock potential and a possible short squeeze. Community members are debating the impact of blockchain initiatives tied to tZERO and speculating about strategic moves by key figures like Ryan Cohen. Bearish investors cite concerns about dilution and cash burn while bullish investors focus on potential new directions for the company.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors anticipate the company's earnings report, with some expecting a positive surprise due to lowered expectations and potential catalysts like a DOJ decision. The community is actively discussing options strategies, with some bulls hedging their bets, while others express concerns about margin pressures and potential negative impacts. Optimism remains among some, citing Warren Buffett's backing and potential for long-term growth despite near-term challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio logged its fourth straight day of gains on Tuesday, climbing to its highest level in nearly a month as shares broke above the 200-day moving average amid optimism from Anktiva trial data showing survival benefits in lung cancer patients.Technical SetupImmunityBio Investor and former UBS analyst David Din&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DavidDin/status/1967895088643895767">said in a post on X</a> that the stock has finally broken out of a long slump dating back to April 2024, now showing a pattern of “higher highs and higher lows.”&nbsp;<img src="https://news.stocktwits-cdn.com/longterm_downward_trend_jpg_bc73477cdd.webp" alt="longterm downward trend.jpg">He pointed to several bullish indicators: a&nbsp;moving average convergence divergence (MACD) crossover (a signal that momentum is shifting upward) and a divergence in relative strength index (showing buying strength building even while the stock had been falling).<img src="https://news.stocktwits-cdn.com/moving_averages_jpg_47d36e8b5a.webp" alt="moving averages.jpg">He also pointed to a positive signal from the Ichimoku Cloud indicator, which provides both forward- and backward-looking views of market trends. For IBRX, the short-term conversion line (blue) has crossed above the longer-term baseline (red), a move that could signal a bullish shift in momentum.<img src="https://news.stocktwits-cdn.com/ichimoku_cloud_jpg_af4d9c4a78.webp" alt="ichimoku cloud.jpg">Din described the move above the 200-day moving average as “huge,” noting the stock had tested this level before but pulled back, and could now make another attempt to push higher.&nbsp;He marked $3.04 as the next Fibonacci level, comparing the setup to past surges he called “God Candles,” where the stock jumped 20%–27% in a single day and cleared multiple technical barriers.He added that Bollinger Bands, which measure volatility, are starting to widen, similar to October 2024 when a sudden spike helped define the stock’s long-term downtrend. With that trendline now broken, Din said there is no major technical ceiling left to stop another strong move.Din also flagged a gap on the chart at $4.50, predicting it would be filled, and noted that shorter-term moving averages are lining up in a bullish fashion: the 21-day average is nearing a crossover of the 50-day, the 50-day is close to crossing the 125-day, and the 200-day is now within reach.Lung Cancer StudyThe stock’s momentum comes alongside clinical data presented at the IASLC 2025 World Conference on Lung Cancer.&nbsp;ImmunityBio reported that its experimental drug, Anktiva, reversed lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer. Patients showed absolute lymphocyte counts above 1,500 cells/μL, achieving a median overall survival of 21.1 months.On Stocktwits, retail sentiment for ImmunityBio was ‘bullish’ amid ‘high’ message volume, with traders upbeat on strong charts, rising volumes, and fresh buying interest.On Stocktwits, one user noted that ImmunityBio shares were trading around $2.90, describing it as a key resistance level, and said the move higher came with strong momentum, as both price and volume continued to exceed recent averages.<stembedurl>https://stocktwits.com/Bc3345/message/628904525</stembedurl>Another user mentioned they had accumulated several thousand shares in anticipation of a breakout. A third said the three-month chart looked “extremely bullish,” while a fourth remarked that they liked the setup and had taken a large position in the stock.<stembedurl>https://stocktwits.com/Stayinvest/message/628914954</stembedurl><stembedurl>https://stocktwits.com/Thorbig/message/628917335</stembedurl><stembedurl>https://stocktwits.com/OliveGardenCPA/message/628901589</stembedurl><a href="https://stocktwits.com/symbol/IBRX">ImmunityBio’s stock</a> has risen 9.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals

The stock’s recent momentum has been fueled by fresh optimism around trial data for its cancer drug Anktiva, which showed survival benefits in resistant lung cancer patients.

Equity

The last few months have seen a resurgence in social media-driven stock trades,&nbsp;resulting in a crop of new meme stocks,&nbsp;including Opendoor, GoPro, Kohl's, and Krispy Kreme.Now, JPMorgan has identified a few more names to keep a tab on. "We are flagging a few stocks that are heavily mentioned on Social Media and have high Retail buying as well as high Hedge fund Shorting," the investment research said in a note to clients, according to<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/11/four-meme-stocks-with-high-social-activity-and-hedge-funds-shorts-according-to-jpmorgan.html">&nbsp;CNBC</a>. "These stocks may experience unexpected flows in case of increased activity."Here are JPMorgan's picks and brief notes on their recent moves:&nbsp;Hims &amp; Hers HealthThe weight loss and health management company's stock has fluctuated significantly between peaks and troughs. Earlier this year, the company entered into a partnership with Novo Nordisk to distribute the latter's Wegovy, a popular GLP-1 weight loss drug. However, a few months later, the Danish pharmaceutical major canceled the partnership, citing Hims &amp; Hers' failure to prevent "knockoff" compounded versions of Wegovy and for engaging in deceptive marketing.U.S. regulators have rapped Hims &amp; Hers for its drug marketing practices, and investors are closely watching the company's moves.Year-to-date gain: 110%Short interest: 31.1%Stocktwits sentiment:&nbsp;Bullish&nbsp;ImmunityBioThe cancer-focused biotech firm has seen interest, driven by clinical-stage Anktiva,&nbsp;designed to boost the immune system's tumor-fighting response, and&nbsp;immunotherapies that target and kill cancer cells. Although the company's stock has mostly&nbsp;traded rangebound this year, shares have jumped double-digit percentages on several occasions in reaction to positive trial data.Year-to-date gain: 0.4%Short interest: 8%Stocktwits sentiment:&nbsp;Bullish&nbsp;Rocket CompaniesThe mortgage and house-owning services firm has seen its stock climb steadily this year, with a recent bump accompanying renewed expectations of a potential lowering of interest rates. The stock hit a 52-week high earlier this week.In March, the Rocket Companies announced a massive $9.4-billion all-stock acquisition of competitor Mr. Cooper Group, lifting investor confidence. The company's business is closely tied to the housing market, which is experiencing a modest rebound.Year-to-date gain: 97%Short interest: 5.3%Stocktwits sentiment:&nbsp;Bullish&nbsp;SoundHound AIAfter a whopping 836% rise in 2024, SoundHound shares have traded comparatively sombrely this year. That said, several analysts have recently begun covering the company, impressed by its voice-based AI technology.In July, the company reported a 217% rise in its second-quarter revenue and increased its sales guidance for the whole year.Year-to-date loss: 29%Short interest: 28.7%Stocktwits sentiment:&nbsp;Bullish&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/rent-the-runway-stocks-plummets-27-after-hours-on-mounting-losses-surging-costs-retail-traders-still-bullish/chw8hPeRdwL">&nbsp;Rent The Runway Stocks Plummets 27% After-Hours On Mounting Losses, Surging Costs — Retail Traders Still Bullish</a>

Traders work on the floor of the New York Stock Exchange during morning trading on August 26, 2025, in New York City. 

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

Meme mania has resurged in the past few months.

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of 0.00% and +0.10%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

ImmunityBio's short interest hit a two-month high of 54% this week, representing an increase from under 30% since early March, despite solid&nbsp;first-quarter operational and financial outcomes.&nbsp;The days-to-cover metric decreased from 14.9 to 14.2 as trading volume increased throughout the last two weeks, according to Ortex data, compiled by The Fly.Shares of the pharma firm closed at $2.84, up 6.37% on Friday, before slipping 1.06% to $2.81 in after-hours trading.The company's Q1 2025 net loss was $129.6 million, a minor improvement from the $134.1 million loss&nbsp;a year earlier.ImmunityBio generated net product revenue of about $16.5 million in Q1 ending March 31, 2025, representing a 129% increase from $7.2 million in Q4 2024.&nbsp;The permanent J-code approval for Anktiva helped providers streamline billing and reimbursement, which led to growth.&nbsp;Anktiva is ImmunityBio’s immunotherapy for non-muscle invasive bladder cancer (NMIBC) that helps address the shortage of BCG (Bacillus Calmette-Guérin), a vaccine used to stimulate the immune system against bladder cancer.&nbsp;Unit sales for Anktiva rose by 150% in Q4 2024, while March sales showed a 69% increase over February due to nearly 200 urology practices enrolling in the rBCG Expanded Access Program to overcome the national BCG shortage.CEO Richard Adcock said that Anktiva's revenue growth remained steady because urologists across rural areas began treating NMIBC carcinoma in situ patients with this drug when other treatment options were scarce.&nbsp;ImmunityBio presented positive long-term clinical data from the QUILT 3.032 study concerning Anktiva benefits for non-muscle invasive bladder cancer patients at the American Urological Association meeting in 2025.On Stocktwits, retail sentiment&nbsp;for IBRX was ‘extremely bullish’ amid ‘high’ message volume.One user expressed optimism about ImmunityBio’s stock potentially reaching and closing at $3 the following day, showing a bullish outlook.&nbsp;<stembedurl>https://stocktwits.com/Gee8tch3/message/615048708</stembedurl>Another user predicted that the stock could rise significantly higher in the coming month.<stembedurl>https://stocktwits.com/BullHustler_/message/615041058</stembedurl>The stock has risen 10.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside

Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

Shares of ImmunityBio, Inc. (IBRX) tumbled 18% on Monday afternoon after the company announced that it received a Refuse to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its bladder cancer treatment application.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.ImmunityBio <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250505409104/en/ImmunityBio-Requests-an-Urgent-Meeting-With-FDA-to-Address-the-Change-in-the-Agencys-Unambiguous-Guidance-on-Jan-2025-to-Submit-a-sBLA-for-NMIBC-BCG-Unresponsive-Papillary-Disease-Following-an-Inconsistent-Refusal-to-File-Letter-on-May-2-2025">received</a> an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).ImmunityBio said that the application was submitted in March after all key decision makers at the FDA encouraged it to submit the application “as soon as possible” at an in-person meeting in January.“At this meeting, all key decision makers were specifically asked and unanimously confirmed that ImmunityBio should submit the sBLA as soon as possible based on the data in the single-arm trial,” the company said. &nbsp;The company also said that it has requested an urgent meeting with the FDA to resolve the inconsistencies between the directives it received in January and the letter it recently received, adding that it was “shocked” by the FDA's “inconsistent response.”The company also highlighted that the FDA approved the use of ANKTIVA plus BCG last year for another scenario of NMIBC based on the same trial data that it referred to in the recently submitted application.On Stocktwits, retail sentiment around ImmunityBio jumped from ‘bearish’ to ‘bullish’ over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_05_at_1_56_52_PM_png_129dd641b3.webp" alt="IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits" width="629" height="68"><figcaption>IBRX's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 5, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is down by 19% this year and over 73% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-escalates-epic-games-fight-with-appeal-stock-falls-after-price-target-cut/chid4BRRb1d">Apple Escalates Epic Games Fight With Appeal – Stock Falls After Price Target Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle invasive bladder cancer (NMIBC).

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after-hours trading.The rally followed the company’s announcement that the U.S. Food and Drug Administration&nbsp;(FDA) has authorized an expanded access program. This program will provide patients in the U.S. with a critical alternative source of BCG, a standard-of-care treatment for bladder cancer.ImmunityBio said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.&nbsp;A recent Sermo survey of 100 U.S. urologists found that 57% could not treat patients over the past year due to a lack of access to TICE BCG.&nbsp;The Serum Institute of India, the world’s largest vaccine manufacturer by volume, developed the alternative BCG source.In European clinical trials for bladder cancer, ImmunityBio said its recombinant BCG vaccine demonstrated strong immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG strains.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Feb_19_0a49f7ee60.png" alt="IBRX sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>IBRX sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for ImmunityBio turned even more bullish, with message volume surging by 450% by the end of Wednesday.&nbsp;Retail traders expressed enthusiasm, with one user calling the news “as good as it can get other than a bid” and another speculating that ImmunityBio’s combination therapy with Anktiva could become the new standard of care, replacing Merck’s BCG.<stembedurl>https://stocktwits.com/KNZtime/message/604937174</stembedurl><stembedurl>https://stocktwits.com/Fishbanger51/message/604931186</stembedurl>Shares of ImmunityBio have gained more than 50% so far this year, though short interest, according to Koyfin, climbed from 6.4% at the start of 2025 to 7.7% by the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE BCG Shortage

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital...

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IBRX News

IBRXImmunityBio Inc